September 10, 2025

Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Evaluation of VWF activity assays shows caplacizumab significantly inhibits VWF-platelet interaction in iTTP, indicating monitoring effectiveness.

Caplacizumab treatment completely inhibits the VWF-GPIb interaction in iTTP patients, allowing for normal platelet counts.
Using five assays, VWF:GPIbM and VWF:RCo showed no activity with caplacizumab, while VWF:Ab produced the highest values.
Assessment utilized commercial assays and the Total-Thrombus-Analysis-System (T-TAS) in 17 iTTP patients effectively treated with caplacizumab.
Findings highlight the VWF:GPIbM and VWF:RCo assays as most suitable for monitoring VWF activity in patients treated with caplacizumab.

Colpani et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Evaluation of VWF activity assays shows caplacizumab significantly inhibits VWF-platelet interaction in iTTP, indicating monitoring effectiveness.